The risk of malignancy and its incidence in early rheumatoid arthritis patients treated with biologic DMARDs
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1478-6362
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
online resource.
- Bibliographic citation
-
The risk of malignancy and its incidence in early rheumatoid arthritis patients treated with biologic DMARDs ; volume:19 ; number:1 ; day:15 ; month:12 ; year:2017 ; pages:1-9 ; date:12.2017
Arthritis Research & Therapy ; 19, Heft 1 (15.12.2017), 1-9, 12.2017
- Keyword
-
Krebs
Onkologie
- Creator
-
Cho, Soo-Kyung
- Contributor
-
Lee, Jiyoung
Han, Minkyung
Bae, Sang-Cheol
Sung, Yoon-Kyoung
SpringerLink (Online service)
- DOI
-
10.1186/s13075-017-1482-y
- URN
-
urn:nbn:de:1111-2018021112633
- Rights
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
14.08.2025, 10:50 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Cho, Soo-Kyung
- Lee, Jiyoung
- Han, Minkyung
- Bae, Sang-Cheol
- Sung, Yoon-Kyoung
- SpringerLink (Online service)
Other Objects (12)
Malignancy Incidence, Management, and Prevention in Patients with Rheumatoid Arthritis
Incidence of malignancy in adult patients with rheumatoid arthritis: a meta-analysis
Erratum to: Incidence of malignancy in adult patients with rheumatoid arthritis: a meta-analysis
A meta-analysis of the incidence of malignancy in adult patients with rheumatoid arthritis
Incidence of Malignancy in the Future?
Administration costs of intravenous biologic drugs for rheumatoid arthritis
Biologic monotherapy in the biologic naïve patient with rheumatoid arthritis (RA): results from an observational study
Risk factors for bone loss in patients with rheumatoid arthritis treated with biologic disease-modifying anti-rheumatic drugs
Do biologic therapies reduce aortic inflammation in rheumatoid arthritis patients?
Synovial phenotypes in rheumatoid arthritis correlate with response to biologic therapeutics
Risk of malignancy and biologic therapy in rheumatic inflammatory diseases: A single-center experience
Retrospective analysis of the incidence of appendiceal neoplasm and malignancy in patients treated for suspected acute appendicitis
Malignancy Incidence, Management, and Prevention in Patients with Rheumatoid Arthritis
Incidence of malignancy in adult patients with rheumatoid arthritis: a meta-analysis
Erratum to: Incidence of malignancy in adult patients with rheumatoid arthritis: a meta-analysis
A meta-analysis of the incidence of malignancy in adult patients with rheumatoid arthritis
Incidence of Malignancy in the Future?
Administration costs of intravenous biologic drugs for rheumatoid arthritis
Biologic monotherapy in the biologic naïve patient with rheumatoid arthritis (RA): results from an observational study
Risk factors for bone loss in patients with rheumatoid arthritis treated with biologic disease-modifying anti-rheumatic drugs
Do biologic therapies reduce aortic inflammation in rheumatoid arthritis patients?
Synovial phenotypes in rheumatoid arthritis correlate with response to biologic therapeutics
Risk of malignancy and biologic therapy in rheumatic inflammatory diseases: A single-center experience
Retrospective analysis of the incidence of appendiceal neoplasm and malignancy in patients treated for suspected acute appendicitis
Malignancy Incidence, Management, and Prevention in Patients with Rheumatoid Arthritis
Incidence of malignancy in adult patients with rheumatoid arthritis: a meta-analysis
Erratum to: Incidence of malignancy in adult patients with rheumatoid arthritis: a meta-analysis
A meta-analysis of the incidence of malignancy in adult patients with rheumatoid arthritis
Incidence of Malignancy in the Future?
Administration costs of intravenous biologic drugs for rheumatoid arthritis
Biologic monotherapy in the biologic naïve patient with rheumatoid arthritis (RA): results from an observational study
Risk factors for bone loss in patients with rheumatoid arthritis treated with biologic disease-modifying anti-rheumatic drugs
Do biologic therapies reduce aortic inflammation in rheumatoid arthritis patients?
Synovial phenotypes in rheumatoid arthritis correlate with response to biologic therapeutics
Risk of malignancy and biologic therapy in rheumatic inflammatory diseases: A single-center experience